Boundless Bio, Inc. reported the fiscal quarter ended March 31, 2026 results: net income Net loss totaled $13.6 million for the first quarter of 2026.
“Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 8, 2026 – Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.”
Material Agreements
Boundless Bio, Inc. terminated Lease Termination Agreement with ARE-10933 North Torrey Pines, LLC valued at $10.0 million (effective 2026-04-13).
“On April 13, 2026, Boundless Bio, Inc. (the "Company") entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the "Lease Termination Agreement") with ARE-10933 North Torrey Pines, LLC ("Landlord"), pursuant to which the Company and Landlord agreed to terminate that certain Lease Agreement dated as of December 20, 2021”
David Hinkle was appointed as Treasurer, principal financial officer, and principal accounting officer at Boundless Bio, Inc..
“As of the Effective Date, David Hinkle, the Company’s Senior Vice President, Finance & Controller, was appointed to also serve as the Company’s Treasurer, principal financial officer, and principal accounting officer.”
Jami Rubin departed as Chief Financial Officer and Treasurer at Boundless Bio, Inc..
“On October 14, 2024, Boundless Bio, Inc. (the “Company”) announced that Jami Rubin, the Company’s Chief Financial Officer and Treasurer, stepped down from her role with the Company.”
Earnings Releases
Boundless Bio, Inc. reported the quarter ended March 31, 2024 results: net income $15.4 million.
“Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights”
Governance Changes
Boundless Bio, Inc.: Amended and restated bylaws effective upon IPO closing, establishing procedures for stockholder proposals and director nominations, and conforming to amended certificate of incorporation (effective 2024-04-02).
“On April 2, 2024, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the Amended and Restated Bylaws), previously approved by the Company’s board of directors to become effective as of immediately prior to, and conditioned upon, the closing of the IPO, became effective. The Amended and Restated Bylaws amend and restate the Company’s bylaws in their entirety to, among other things: (i) establish procedures relating to the presentation of stockholder proposals at stockholder meetings; (ii) establish procedures relating to the nomination of directors; and (iii) conform to the amended provisions of the Restated Certificate.”
Governance Changes
Boundless Bio, Inc.: Amended and restated certificate of incorporation effective upon IPO closing, including increase in authorized common stock to 700,000,000 shares, authorization of 70,000,000 shares of undesignated preferred stock, classified board of directors with staggered three-year terms, removal of directors o (effective 2024-04-02).
“The Restated Certificate amends and restates the Company’s amended and restated certificate of incorporation, in its entirety to, among other things: (i) increase the authorized number of shares of common stock to 700,000,000 shares; (ii) authorize 70,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company’s board of directors in one or more series; (iii) establish a classified board of directors, divided into three classes, each of whose members will serve for staggered three-year terms; (iv) provide that directors may be removed from office only for cause by the affirmative vote of the holders of at least two-thirds of the Company’s outstanding capital stock then entitled to vote in an election of directors; (v) eliminate the ability of the Company’s stockholders to take action by written consent in lieu of a meeting; and (vi) provide that, unless the Company consents in writing to the selection of an alternative forum, the federal district”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.